Premium
Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data
Author(s) -
Einolf H J,
Chen L,
Fahmi O A,
Gibson C R,
Obach R S,
Shebley M,
Silva J,
Sinz M W,
Unadkat J D,
Zhang L,
Zhao P
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.170
Subject(s) - cyp3a , cmax , in vivo , false positive paradox , pharmacology , pharmacokinetics , cyp3a4 , drug , chemistry , computational biology , in vitro , cytochrome p450 , medicine , biology , mathematics , statistics , biochemistry , microsome , metabolism , microbiology and biotechnology
Several drug–drug interaction (DDI) prediction models were evaluated for their ability to identify drugs with cytochrome P450 (CYP)3A induction liability based on in vitro mRNA data. The drug interaction magnitudes of CYP3A substrates from 28 clinical trials were predicted using (i) correlation approaches (ratio of the in vivo peak plasma concentration ( C max ) to in vitro half‐maximal effective concentration (EC 50 ); and relative induction score), (ii) a basic static model (calculated R 3 value), (iii) a mechanistic static model (net effect), and (iv) mechanistic dynamic (physiologically based pharmacokinetic) modeling. All models performed with high fidelity and predicted few false negatives or false positives. The correlation approaches and basic static model resulted in no false negatives when total C max was incorporated; these models may be sufficient to conservatively identify clinical CYP3A induction liability. Mechanistic models that include CYP inactivation in addition to induction resulted in DDI predictions with less accuracy, likely due to an overprediction of the inactivation effect. Clinical Pharmacology & Therapeutics (2014); 95 2, 216–227. doi: 10.1038/clpt.2013.170